The economic value of knowing BRCA status:
BRCA
BRCA1
BRCA2
cost-effectiveness
olaparib
ovarian cancer
recurrent epithelial ovarian
Journal
Expert review of pharmacoeconomics & outcomes research
ISSN: 1744-8379
Titre abrégé: Expert Rev Pharmacoecon Outcomes Res
Pays: England
ID NLM: 101132257
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
pubmed:
25
1
2023
medline:
25
2
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
This study aimed to estimate the incremental lifetime effects, costs, and net monetary benefit (NMB) of knowing Incremental NMB (INMB) was calculated as the average net monetized benefit of knowing Knowing BRCA information for ROC patients provided an additional monetized value of $3,528 in (payer) and $3,194 (society). Escalated to all ROC patients in the U.S. and future incidence ROC estimates, knowing The economic value of knowing
Sections du résumé
BACKGROUND
UNASSIGNED
This study aimed to estimate the incremental lifetime effects, costs, and net monetary benefit (NMB) of knowing
METHODS
UNASSIGNED
Incremental NMB (INMB) was calculated as the average net monetized benefit of knowing
RESULTS
UNASSIGNED
Knowing BRCA information for ROC patients provided an additional monetized value of $3,528 in (payer) and $3,194 (society). Escalated to all ROC patients in the U.S. and future incidence ROC estimates, knowing
CONCLUSIONS
UNASSIGNED
The economic value of knowing
Identifiants
pubmed: 36691923
doi: 10.1080/14737167.2023.2169136
doi:
Substances chimiques
BRCA1 protein, human
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM